Document Detail


Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits.
MedLine Citation:
PMID:  9369826     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Recent reports have suggested that the use of indomethacin for tocolysis may independently increase the risk for major adverse neonatal events such as intraventricular hemorrhage and necrotizing enterocolitis. The objective of this study was to determine whether this potential risk of indomethacin is outweighed by the benefit of delivery delay at gestational ages < 32 weeks. STUDY DESIGN: We constructed separate decision trees to compare strategies of tocolysis with indomethacin versus no tocolysis for hypothetic cohorts of patients with idiopathic preterm labor at 24, 26, 28, 30, and 32 weeks' gestation. Probabilities for these decision models, including estimates of indomethacin efficacy and the potential for increase in adverse neonatal events with indomethacin, were obtained from the medical literature. The primary outcome was the number of expected adverse neonatal events per 1000 women for each strategy at each gestational age. RESULTS: In the base case analysis tocolysis with indomethacin was a more favorable strategy than no tocolysis across all gestational ages that we studied. As expected, the difference in the number of events between the two strategies declined with advancing gestational age because of a decreasing baseline risk for adverse neonatal events as gestational age increased. The models at 26, 28, 30, or 32 weeks were not sensitive to our estimates of indomethacin efficacy, nor to our estimates of baseline neonatal morbidity or steroid efficacy, or to the relative increase in some neonatal morbidities with indomethacin use. CONCLUSIONS: On the basis of current estimates, the benefits of indomethacin outweigh the potential risks to the neonate at gestational ages < or = 32 weeks. Thus the use of indomethacin for tocolysis at these ages is a reasonable strategy.
Authors:
G A Macones; C A Robinson
Related Documents :
12887066 - Cardiac catheterisation in infants weighing less than 2500 grams.
7162876 - Serum digoxin levels in neonates whose weights are less than 1,500 grams.
19171636 - Genetic contribution to patent ductus arteriosus in the premature newborn.
19843236 - Prophylactic indomethacin in extremely premature infants between 23 and 24 weeks gestat...
2586566 - The relation of aspirin use during the first trimester of pregnancy to congenital cardi...
2572806 - Early infant mortality in west germany before and after chernobyl.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  177     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-12-05     Completed Date:  1997-12-05     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  819-24     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, University of Pennsylvania Health System, Philadelphia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cerebral Hemorrhage / chemically induced
Decision Support Techniques
Enterocolitis, Pseudomembranous / chemically induced
Female
Gestational Age*
Humans
Indomethacin / adverse effects*,  therapeutic use*
Infant, Newborn
Obstetric Labor, Premature / drug therapy*
Pregnancy
Risk Factors
Tocolytic Agents / adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Tocolytic Agents; 53-86-1/Indomethacin
Comments/Corrections
Comment In:
Am J Obstet Gynecol. 1998 Apr;178(4):873-4   [PMID:  9579464 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management options in women with preterm uterine contractions: a randomized clinical trial.
Next Document:  Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interl...